Earnings bulletin: Johnson & Johnson’s second quarter of 2019

By | July 17, 2019

Johnson & Johnson kicked off the second-quarter earnings season Tuesday, reporting that its pharma unit outperformed struggling consumer healthcare and medical device segments. Pharma posted sales growth of 1.7% and operational growth of 4.4% to hit $ 10.53 billion in sales.

Across J&J’s entire business, the company’s revenue sank 1.3% to $ 20.56 billion. At the same time, earnings jumped 41.8% thanks to a sale in medical devices that brought in about $ 2 billion before taxes. That revenue figure and adjusted earnings per share of $ 2.58 both beat analyst estimates.

With the performance, Johnson & Johnson increased its sales guidance for the year to between $ 82.4 billion and $ 83.2 billion, up from April’s guidance of $ 82 billion to $ 82.8 billion.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

RELATED: J&J execs have plenty to brag about in pharma. Why downplay Xarelto, Zytiga woes?

Within pharma, blockbuster immunology med Remicade continued to slump thanks to biosimilar pressure; sales for that med sank 16.2% globally to $ 1.1 billion for the quarter. Zytiga suffered from generic competition, and Xarelto posted a 19% decline in the U.S. thanks to new discounting rules in Medicare.

On the flip side, Stelara, Tremfya, Invega, Darzalex, Imbruvica, Opsumit, Uptravi, and Prezista grew by double digit percentages.

Read more on

FiercePharma: Pharma